Discovery of 5-[5-Fluoro-2-oxo-1,2- dihydroindol-(3<i>Z</i>)-ylidenemethyl]-2,4- dimethyl-1<i>H</i>-pyrrole-3-carboxylic Acid (2-Diethylaminoethyl)amide, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial and Platelet-Derived Growth Factor Receptor Tyrosine Kinase

Cherrington, J. M.; Strawn, L. M.; Shawver, L. K. New paradigms for the treatment of cancer; the role of anti-angiogenesis agents. InAdvances inCancer Research, 1st ed.; Klein, G., Van de Woude, G. F., Eds.  Academic Press:  San Diego, CA, 2000; Vol. 70, pp 1−38.

Gale N. W., 1999, Genes Dev., 13, 1066

Ferrara N., 2000, Curr. Opin. Biotechnol., 11, 624, 10.1016/S0958-1669(00)00153-1

Rosenkranz S., 1999, Growth Factors, 16, 216, 10.3109/08977199909002130

Sun L., 1998, J. Med. Chem., 41, 2603

Laird A. D., 2000, Cancer Res., 60, 4160

Sun L., 1999, J. Med. Chem., 42, 5130

Mendel D. B., 2003, Clin. Cancer Res., 9, 337

Fong A. T. T., 1999, Cancer Res., 59, 106

Hennequin L. F., 2002, J. Med. Chem., 45, 1312, 10.1021/jm011022e

Liao A. T., 2002, Blood, 100, 593

Fong T. A. T., 1999, Cancer Res., 59, 106

Mendel D. B., 2002, vivo antitumor and mechanism of action studies of SU11248, a potent and selective inhibitor of the VEGF and PDGF receptors. Presented at the American Association for Cancer Reserch